"instanceType","description","label","uuid:ID","rationale","id","name"
"StudyDesign","The main design for the study","","736cd441-cb5a-4e00-b0cb-2d76b0897a5e","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign_1","Study Design 1"
